Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

NCT04410445 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

765

Enrollment

INDUSTRY

Sponsor class

Stopped (Sponsor decision)

Conditions

Melanoma
Melanoma Stage III
Melanoma Stage IV
Melanoma (Skin)

Interventions

BIOLOGICAL: Bempegaldesleukin
BIOLOGICAL: Nivolumab

Sponsor

Nektar Therapeutics

Collaborators

[object Object]